Literature DB >> 11718314

An exploration of the history and controversies surrounding MDMA and MDA.

A R Pentney1.   

Abstract

In existence for nearly a century, 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") have gained quite a reputation. Perceived by some as dangerous neurotoxins, and by others as potential psychotherapeutics, these compounds have become a center of controversy among academics and law enforcement officials, and in the process have gained extensive media exposure. The classification of these drugs as illicit, controlled substances in the United States has not prevented their use, and MDMA, or Ecstasy, is currently one of the most popular substances used recreationally in North America. The scheduling of MDMA and MDA has, however, led to the distribution of contaminated, or falsely represented, Ecstasy tablets, and prevented responsible research into the detrimental and therapeutic effects of these drugs. A look at the history of these compounds suggests that they have the potential to be used safely as psychotherapeutic tools, and that the legal status of MDMA and MDA may be worth reconsidering.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11718314     DOI: 10.1080/02791072.2001.10400568

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  16 in total

1.  [The early history of "Ecstasy"].

Authors:  U Benzenhöfer; T Passie
Journal:  Nervenarzt       Date:  2006-01       Impact factor: 1.214

Review 2.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

Review 3.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

5.  Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Authors:  Matthew J Baggott; Jennifer D Siegrist; Gantt P Galloway; Lynn C Robertson; Jeremy R Coyle; John E Mendelson
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

6.  "Ecstasy" to addiction: Mechanisms and reinforcing effects of three synthetic cathinone analogs of MDMA.

Authors:  Sean B Dolan; Zhenglan Chen; Renqi Huang; Michael B Gatch
Journal:  Neuropharmacology       Date:  2018-01-31       Impact factor: 5.250

7.  Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.

Authors:  Jakob A Shimshoni; Ilan Winkler; Ezekiel Golan; David Nutt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-20       Impact factor: 3.000

8.  Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.

Authors:  Tsadik T Abraham; Allan J Barnes; Ross H Lowe; Erin A Kolbrich Spargo; Garry Milman; Stephane O Pirnay; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

9.  Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2008-06       Impact factor: 3.681

Review 10.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.